Adverse drug reactions.
K Patton, D C Borshoff
https://pubmed.ncbi.nlm.nih.gov/29313907/Actively Recruiting
Led by The University of Hong Kong · Updated on 2026-04-29
440
Participants Needed
4
Research Sites
104 weeks
Total Duration
Researchers are evaluating a combined nurse-allergist approach versus the traditional allergist-led approach for penicillin allergy delabeling. The study aims to assess the effectiveness and safety of these methods, their impact on patients quality of life, and differences in resource use and cost-effectiveness. This approach considers patient risk levels to improve the delabeling process while maintaining comparable success and safety. Participants will receive either a nurse-led penicillin allergy delabeling service, where nurses assess risk and collaborate with allergists for low-risk cases, or an allergist-led service handling all risk levels. These diagnostic tests help categorize patients and guide the delabeling process through two distinct study groups. During the study, participants clinical and demographic data will be collected, and their progress monitored for six months. Researchers will measure outcomes like delabeling success, health-related quality of life, antibiotic use, and immunocompetence status. The study is observational, involving patients receiving care at participating hospitals, with follow-up to evaluate initial and recurrent labeling effects and age group differences.
CONDITIONS
Provocation After Nurse-Directed Assessment (PANDA) Study
E
Elaine Lee
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The University of Hong Kong
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 week
Participants undergo penicillin allergy risk assessment and categorization either by nurses in collaboration with allergists or by allergists alone to determine eligibility for delabeling.
1 to 2 visits depending on risk assessment
Duration - 6 months
Participants are observed over 6 months to assess delabeling success, quality of life changes, antibiotic usage, and other health outcomes.
Periodic visits or assessments over 6 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
K Patton, D C Borshoff
https://pubmed.ncbi.nlm.nih.gov/29313907/Elissa M Abrams, David A Khan
https://pubmed.ncbi.nlm.nih.gov/29712672/Zahra Pourpak, Mohammad R Fazlollahi, Fatemeh Fattahi
https://pubmed.ncbi.nlm.nih.gov/19075990/D C Classen, S L Pestotnik, R S Evans...
https://pubmed.ncbi.nlm.nih.gov/9002492/Benno Schnyder, Werner J Pichler
https://pubmed.ncbi.nlm.nih.gov/19252115/The University of Hong Kong
Lead Sponsor